Figure S7 from the EZH2–PHACTR2–AS1–Ribosome Axis Induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer

Wenhui Chu,Zhaodong Xi,Qi Lei,Yenan Fu,Peng Wang,Wei Zhao,J. Du,Jing Zhang,Jun Zhan,Yunling Wang,Weiguo Zhu,Yu,Hongquan Zhang

DOI: https://doi.org/10.1158/0008-5472.24895357.v1

2023-01-01

Abstract:Figure S7 shows the PHACTR2-AS1 expression in human tumor tissues.

What problem does this paper attempt to address?

Figure S4 from The EZH2–PHACTR2–AS1–Ribosome Axis induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer

Wenhui Chu,Xi Zhang,Lihua Qi,Yenan Fu,Peng Wang,Wei Zhao,Juan Du,Jing Zhang,Jun Zhan,Yunling Wang,Wei-Guo Zhu,Yu Yu,Hongquan Zhang

DOI: https://doi.org/10.1158/0008-5472.24895366.v1

2023-01-01

Abstract:Figure S4 shows taht PHACTR2-AS1 depletion induced genome instability
Figure S2 from the EZH2–PHACTR2–AS1–Ribosome Axis Induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer

Wenhui Chu,Xi Zhang,Lihua Qi,Yenan Fu,Peng Wang,Wei Zhao,Juan Du,Jing Zhang,Jun Zhan,Yunling Wang,Wei-Guo Zhu,Yu,Hongquan Zhang

DOI: https://doi.org/10.1158/0008-5472.24895372.v1

2023-01-01

Abstract:Figure S2 shows that PHACTR2-AS1 inhibits pre-rRNA.
The EZH2–PHACTR2–AS1–Ribosome Axis Induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer

Wenhui Chu,Xi Zhang,Lihua Qi,Yenan Fu,Peng Wang,Wei Zhao,Juan Du,Jing Zhang,Jun Zhan,Yunling Wang,Wei-Guo Zhu,Yu,Hongquan Zhang

DOI: https://doi.org/10.1158/0008-5472.can-19-3326

IF: 11.2

2020-01-01

Cancer Research

Abstract:Aberrant activation of histone methyltransferase EZH2 and ribosome synthesis strongly associate with cancer development and progression. We previously found that EZH2 regulates RNA polymerase III-transcribed 5S ribosomal RNA gene transcription. However, whether EZH2 regulates ribosome synthesis is still unknown. Here, we report that EZH2 promotes ribosome synthesis by targeting and silencing a long noncoding RNA PHACTR2-AS1. PHACTR2-AS1 directly bound ribosome DNA genes and recruited histone methyltransferase SUV39H1, which in turn triggered H3K9 methylation of these genes. Depletion of PHACTR2-AS1 resulted in hyperactivation of ribosome synthesis and instability of ribosomal DNA, which promoted cancer cell proliferation and metastasis. Administration of PHACTR2-AS1-30nt-RNA, which binds to SUV39H1, effectively inhibited breast cancer growth and lung metastasis in mice. PHACTR2-AS1 was downregulated in breast cancer patients, where lower PHACTR2-AS1 expression promoted breast cancer development and correlated with poor patient outcome. Taken together, we demonstrate that PHACTR2-AS1 maintains a H3K9 methylation-marked silent state of ribosomal DNA genes, comprising a regulatory axis that controls breast cancer growth and metastasis. SIGNIFICANCE: These findings reveal that EZH2 mediates ribosomal DNA stability via silencing of PHACTR2-AS1, representing a potential therapeutic target to control breast cancer growth and metastasis.
Supplementary Methods, Figures 1-4 from Rho Kinase Phosphorylation Promotes Ezrin-Mediated Metastasis in Hepatocellular Carcinoma

Yong Chen,Dongmei Wang,Zhen Guo,Jun Zhao,Bing Wu,Hui Deng,Ti Zhou,Hongjun Xiang,Fei Gao,Xue Yu,Jian Liao,Tarsha Ward,Peng Xia,Chibuzo Emenari,Xia Ding,Winston Thompson,Kelong Ma,Jingde Zhu,Felix Aikhionbare,Kefen Dou,Shi-Yuan Cheng,Xuebiao Yao

DOI: https://doi.org/10.1158/0008-5472.22387211

2023-01-01

Abstract:Supplementary Methods, Figures 1-4 from Rho Kinase Phosphorylation Promotes Ezrin-Mediated Metastasis in Hepatocellular Carcinoma
Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

Jiahui Mou,Meijun Huang,Feifei Wang,Xiaoding Xu,Hanqi Xie,Henglei Lu,Mingyang Li,Yu Li,Weiwen Kong,Jing Chen,Ying Xiao,Yiding Chen,Chaochen Wang,Jin Ren

DOI: https://doi.org/10.1158/1541-7786.22527890

2023-01-01

Abstract:Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis
Rho Kinase Phosphorylation Promotes Ezrin-Mediated Metastasis in Hepatocellular Carcinoma

Yong Chen,Dongmei Wang,Zhen Guo,Jun Zhao,Bing Wu,Hui Deng,Ti Zhou,Hongjun Xiang,Fei Gao,Xue Yu,Jian Liao,Tarsha Ward,Peng Xia,Chibuzo Emenari,Xia Ding,Winston Thompson,Kelong Ma,Jingde Zhu,Felix Aikhionbare,Kefen Dou,Shi-Yuan Cheng,Xuebiao Yao

DOI: https://doi.org/10.1158/0008-5472.can-09-4683

IF: 11.2

2011-01-01

Cancer Research

Abstract:AbstractDuring progression of hepatocellular carcinoma, multiple genetic and epigenetic alterations act to posttranslationally modulate the function of proteins that promote cancer invasion and metastasis. To define such abnormalities that contribute to liver cancer metastasis, we carried out a proteomic comparison of primary hepatocellular carcinoma and samples of intravascular thrombi from the same patient. Mass spectrometric analyses of the liver cancer samples revealed a series of acidic phospho-isotypes associated with the intravascular thrombi samples. In particular, we found that Thr567 hyperphosphorylation of the cytoskeletal protein ezrin was tightly correlated to an invasive phenotype of clinical hepatocellular carcinomas and to poor outcomes in tumor xenograft assays. Using phospho-mimicking mutants, we showed that ezrin phosphorylation at Thr567 promoted in vitro invasion by hepatocarcinoma cells. Phospho-mimicking mutant ezrinT567D, but not the nonphosphorylatable mutant ezrinT567A, stimulated formation of membrane ruffles, suggesting that Thr567 phosphorylation promotes cytoskeletal-membrane remodeling. Importantly, inhibition of Rho kinase, either by Y27632 or RNA interference, resulted in inhibition of Thr567 phosphorylation and a blockade to cell invasion, implicating Rho kinase-ezrin signaling in hepatocellular carcinoma cell invasion. Our findings suggest a strategy to reduce liver tumor metastasis by blocking Rho kinase-mediated phosphorylation of ezrin. Cancer Res; 71(5); 1721–9. ©2011 AACR.
Supplementary Figure S6 from PRMT7 Induces Epithelial-to-Mesenchymal Transition and Promotes Metastasis in Breast Cancer

Ruosi Yao,Hao Jiang,Yuhui Ma,Liping Wang,Lin Wang,Juan Du,Pingfu Hou,Yanyan Gao,Li Zhao,Guannan Wang,Yu Zhang,Dong-Xu Liu,Baiqu Huang,Jun Lu

DOI: https://doi.org/10.1158/0008-5472.22402983

2023-01-01

Abstract:Effect of PRMT7 on HDAC3 protein expression and location.
Supplementary Methods, Figures 1-9, Tables 2-6 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Alfred S.L. Cheng,Suki S. Lau,Yangchao Chen,Yutaka Kondo,May S. Li,Hai Feng,Arthur K. Ching,Kin F. Cheung,Hoi K. Wong,Joanna H. Tong,Hongchuan Jin,Kwong W. Choy,Jun Yu,Ka F. To,Nathalie Wong,Tim H.-M. Huang,Joseph J.Y. Sung

DOI: https://doi.org/10.1158/0008-5472.22395239.v1

2023-01-01

Abstract:Supplementary Methods, Figures 1-9, Tables 2-6 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis
Supplementary Figure S7 from PRMT7 Induces Epithelial-to-Mesenchymal Transition and Promotes Metastasis in Breast Cancer

Ruosi Yao,Hao Jiang,Yanhe Ma,Liping Wang,Lin Wang,Jie Du,Pingfu Hou,Y. Gao,Li Zhao,Guannan Wang,Yu Zhang,Dong-Xu Liu,Baiqu Huang,Jun Lü

DOI: https://doi.org/10.1158/0008-5472.22402980.v1

2023-01-01

Abstract:Effect of PRMT7 on YY1 protein expression, and the interplay between YY1 and HDAC3.
Supplementary Table 7 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Alfred S.L. Cheng,Suki S. Lau,Yangchao Chen,Yutaka Kondo,May S. Li,Hai Feng,Arthur K. Ching,Kin F. Cheung,Hoi K. Wong,Joanna H. Tong,Hongchuan Jin,Kwong W. Choy,Jun Yu,Ka F. To,Nathalie Wong,Tim H.-M. Huang,Joseph J.Y. Sung

DOI: https://doi.org/10.1158/0008-5472.22395233

2023-01-01

Abstract:Supplementary Table 7 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis
Figure S2 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Binghao Li,Zhan Wang,Hao Wu,Xue Meng,Peng Lin,Shengdong Wang,Nong Lin,Xin Huang,Weibo Pan,Meng Li,Xiu‐Ping Yan,Hao Qu,Lingling Sun,Hengyuan Li,Yan Wu,Wangsiyuan Teng,Zenan Wang,Xingzhi Zhou,Huabiao Chen,Mark C. Poznansky,Zhaoming Ye

DOI: https://doi.org/10.1158/0008-5472.22419846.v1

2023-01-01

Abstract:Supplementary figure S2. Gating strategies for flow cytometry analyses.
Supplementary Figure S8 from PRMT7 Induces Epithelial-to-Mesenchymal Transition and Promotes Metastasis in Breast Cancer

Ruosi Yao,Hao Jiang,Yuhui Ma,Liping Wang,Lin Wang,Juan Du,Pingfu Hou,Yanyan Gao,Li Zhao,Guannan Wang,Yu Zhang,Dong-Xu Liu,Baiqu Huang,Jun Lu

DOI: https://doi.org/10.1158/0008-5472.22402977

2023-01-01

Abstract:Effect of PRMT7 on tumor cell growth.
Supplementary Figure S5 from PRMT7 Induces Epithelial-to-Mesenchymal Transition and Promotes Metastasis in Breast Cancer

Ruosi Yao,Hao Jiang,Yuhui Ma,Liping Wang,Lin Wang,Juan Du,Pingfu Hou,Yanyan Gao,Li Zhao,Guannan Wang,Yu Zhang,Dong-Xu Liu,Baiqu Huang,Jun Lu

DOI: https://doi.org/10.1158/0008-5472.22402989

2023-01-01

Abstract:The subcelluar location of PRMT7 and Luciferase reporter assays of N-cadherin and Vimentin promoter activities.
Methylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis

Zhongwei Li,Diandian Wang,Jun Lu,Baiqu Huang,Yibo Wang,Meichen Dong,Dongmei Fan,Hongyuan Li,Yanyan Gao,Pingfu Hou,Minle Li,Hui Liu,Zhen-Qiang Pan,Junnian Zheng,Jin Bai

DOI: https://doi.org/10.1038/s41418-020-00615-9

IF: 12.067

2020-09-07

Cell Death and Differentiation

Abstract:Enhancer of zeste homolog 2 (EZH2), a key histone methyltransferase and EMT inducer, is overexpressed in diverse carcinomas, including breast cancer. However, the molecular mechanisms of EZH2 dysregulation in cancers are still largely unknown. Here, we discover that EZH2 is asymmetrically dimethylated at R342 (meR342-EZH2) by PRMT1. meR342-EZH2 was found to inhibit the CDK1-mediated phosphorylation of EZH2 at T345 and T487, thereby attenuating EZH2 ubiquitylation mediated by the E3 ligase TRAF6. We also demonstrate that meR342-EZH2 resulted in a decrease in EZH2 target gene expression, but an increase in breast cancer cell EMT, invasion and metastasis. Moreover, we confirm the positive correlations among PRMT1, meR342-EZH2 and EZH2 expression in the breast cancer tissues. Finally, we report that high expression levels of meR342-EZH2 predict a poor clinical outcome in breast cancer patients. Our findings may provide a novel diagnostic target and promising therapeutic target for breast cancer metastasis.

cell biology,biochemistry & molecular biology
Supplementary Figure 2 from Characterization of a Novel Mechanism of Genomic Instability Involving the SEI1/SET/NM23H1 Pathway in Esophageal Cancers

Yan Li,Chang-Jun Nie,Liang Hu,Yanru Qin,Hai-bo Liu,Ting-Ting Zeng,Leilei Chen,Li Fu,Wen Deng,Shu-Peng Chen,Wei-Hua Jia,Chunyu Zhang,Dan Xie,Xin-Yuan Guan

DOI: https://doi.org/10.1158/0008-5472.22382904

2023-01-01

Abstract:Supplementary Figure 2 from Characterization of a Novel Mechanism of Genomic Instability Involving the SEI1/SET/NM23H1 Pathway in Esophageal Cancers
Integration of Estrogen and Wnt Signaling Circuits by the Polycomb Group Protein EZH2 in Breast Cancer Cells.

Bin Shi,Jing Liang,Xiaohan Yang,Yan Wang,Youna Zhao,Huijian Wu,Luyang Sun,Ying Zhang,Yupeng Chen,Ruifang Li,Yu Zhang,Mei Hong,Yongfeng Shang

DOI: https://doi.org/10.1128/mcb.00162-07

IF: 5.069

2007-01-01

Molecular and Cellular Biology

Abstract:Essential for embryonic development, the polycomb group protein enhancer of zeste homolog 2 (EZH2) is overexpressed in breast and prostate cancers and is implicated in the growth and aggression of the tumors. The tumorigenic mechanism underlying EZH2 overexpression is largely unknown. It is believed that EZH2 exerts its biological activity as a transcription repressor. However, we report here that EZH2 functions in gene transcriptional activation in breast cancer cells. We show that EZH2 transactivates genes that are commonly targeted by estrogen and Wnt signaling pathways. We demonstrated that EZH2 physically interacts directly with estrogen receptor a and beta-catenin, thus connecting the estrogen and Wnt signaling circuitries, functionally enhances gene transactivation by estrogen and Writ pathways, and phenotypically promotes cell cycle progression. In addition, we identified the transactivation activity of EZH2 in its two N-terminal domains and demonstrated that these structures serve as platforms to connect transcription factors and the Mediator complex. Our experiments indicated that EZH2 is a dual function transcription regulator with a dynamic activity, and we provide a mechanism for EZH2 in tumorigenesis.
ZRANB1 is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer.

Peijing Zhang,Zhenna Xiao,Shouyu Wang,Mutian Zhang,Yongkun Wei,Qinglei Hang,Jongchan Kim,Fan Yao,Cristian Rodriguez-Aguayo,Baochau N Ton,Minjung Lee,Yumeng Wang,Zhicheng Zhou,Liyong Zeng,Xiaoyu Hu,Sarah E Lawhon,Ashley N Siverly,Xiaohua Su,Jia Li,Xiaoping Xie,Xuhong Cheng,Liang-Chiu Liu,Hui-Wen Chang,Shu-Fen Chiang,Gabriel Lopez-Berestein,Anil K Sood,Junjie Chen,M James You,Shao-Cong Sun,Han Liang,Yun Huang,Xianbin Yang,Deqiang Sun,Yutong Sun,Mien-Chie Hung,Li Ma

DOI: https://doi.org/10.1016/j.celrep.2018.03.078

IF: 8.8

2018-01-01

Cell Reports

Abstract:Although EZH2 enzymatic inhibitors have shown antitumor effects in EZH2-mutated lymphoma and ARID1A-mutated ovarian cancer, many cancers do not respond because EZH2 can promote cancer independently of its histone methyltransferase activity. Here we identify ZRANB1 as the EZH2 deubiquitinase. ZRANB1 binds, deubiquitinates, and stabilizes EZH2. Depletion of ZRANB1 in breast cancer cells results in EZH2 destabilization and growth inhibition. Systemic delivery of ZRANB1 small interfering RNA (siRNA) leads to marked antitumor and antimetastatic effects in preclinical models of triple-negative breast cancer (TNBC). Intriguingly, a small-molecule inhibitor of ZRANB1 destabilizes EZH2 and inhibits the viability of TNBC cells. In patients with breast cancer, ZRANB1 levels correlate with EZH2 levels and poor survival. These findings suggest the therapeutic potential for targeting the EZH2 deubiquitinase ZRANB1.
Mutant P53 Induces EZH2 Expression and Promotes Epithelial-Mesenchymal Transition by Disrupting P68-Drosha Complex Assembly and Attenuating Mir-26A Processing

Fei-Zhou Jiang,Yin-Yan He,Hui-Hui Wang,Hui-Lin Zhang,Jian Zhang,Xiao-Fang Yan,Xiao-Jun Wang,Qi Che,Jie-Qi Ke,Zheng Chen,Huan Tong,Yong-Li Zhang,Fang-Yuan Wang,Yi-Ran Li,Xiao-Ping Wan

DOI: https://doi.org/10.18632/oncotarget.6350

2015-01-01

Oncotarget

Abstract:The tumor suppressor p53 and the transcriptional repressor Enhancer of Zeste Homolog 2 (EZH2) have both been implicated in the regulation of epithelialmesenchymal transition (EMT) and tumor metastasis via their impacts on microRNA expression.Here, we report that mutant p53 (mutp53) promotes EMT in endometrial carcinoma (EC) by disrupting p68-Drosha complex assembly.Overexpression of mutp53 has the opposite effect of wild-type p53 (WTp53), repressing miR-26a expression by reducing pri-miR-26a-1 processing in p53-null EC cells. Re-expression of miR-26a in mutp53 EC cells decreases cell invasion and promotes mesenchymalepithelial transition (MET). Rescuing miR-26a expression also inhibits EZH2, N-cadherin, Vimentin, and Snail expression and induces E-cadherin expression bothin vitro and in vivo.Moreover, patients with higher serum miR-26a levels have a better survival rate.These results suggest that p53 gain-of-function mutations accelerate EC tumor progression and metastasis by interfering with Drosha and p68 binding and pri-miR-26a-1 processing, resulting in reduced miR-26a expression and EZH2 overexpression.
EZH2 Takes the Stage when BRCA1 Loses.

Lan Wang,Haojie Huang

DOI: https://doi.org/10.4161/cc.26785

2013-01-01

Abstract:Click to increase image sizeClick to decrease image sizeKeywords:: gene silencingepigeneticsEZH2BRCA1cancer therapynon-coding RNAPRC2embryonic stem cellHOTAIRbasal-like breast cancerThis article is related to:
Supplementary Figure 2 from HNRNPAB Induces Epithelial–Mesenchymal Transition and Promotes Metastasis of Hepatocellular Carcinoma by Transcriptionally Activating <i>SNAIL</i>

Zheng-Jun Zhou,Zhi Dai,Shao-Lai Zhou,Zhi-Qiang Hu,Qing Chen,Yi-Ming Zhao,Ying-Hong Shi,Qiang Gao,Wei-Zhong Wu,Shuang-Jian Qiu,Jian Zhou,Jia Fan

DOI: https://doi.org/10.1158/0008-5472.22400150

2023-01-01

Abstract:<p>PDF file - 110K, Supplementary Figure S2. The effect of hnRNPAB on tumor growth and metastasis in vivo.</p>

Figure S7 from the EZH2–PHACTR2–AS1–Ribosome Axis Induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer

Figure S4 from The EZH2–PHACTR2–AS1–Ribosome Axis induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer

Figure S2 from the EZH2–PHACTR2–AS1–Ribosome Axis Induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer

The EZH2–PHACTR2–AS1–Ribosome Axis Induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer

Supplementary Methods, Figures 1-4 from Rho Kinase Phosphorylation Promotes Ezrin-Mediated Metastasis in Hepatocellular Carcinoma

Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

Rho Kinase Phosphorylation Promotes Ezrin-Mediated Metastasis in Hepatocellular Carcinoma

Supplementary Figure S6 from PRMT7 Induces Epithelial-to-Mesenchymal Transition and Promotes Metastasis in Breast Cancer

Supplementary Methods, Figures 1-9, Tables 2-6 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Supplementary Figure S7 from PRMT7 Induces Epithelial-to-Mesenchymal Transition and Promotes Metastasis in Breast Cancer

Supplementary Table 7 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Figure S2 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Supplementary Figure S8 from PRMT7 Induces Epithelial-to-Mesenchymal Transition and Promotes Metastasis in Breast Cancer

Supplementary Figure S5 from PRMT7 Induces Epithelial-to-Mesenchymal Transition and Promotes Metastasis in Breast Cancer

Methylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis

Supplementary Figure 2 from Characterization of a Novel Mechanism of Genomic Instability Involving the SEI1/SET/NM23H1 Pathway in Esophageal Cancers

Integration of Estrogen and Wnt Signaling Circuits by the Polycomb Group Protein EZH2 in Breast Cancer Cells.

ZRANB1 is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer.

Mutant P53 Induces EZH2 Expression and Promotes Epithelial-Mesenchymal Transition by Disrupting P68-Drosha Complex Assembly and Attenuating Mir-26A Processing

EZH2 Takes the Stage when BRCA1 Loses.

Supplementary Figure 2 from HNRNPAB Induces Epithelial–Mesenchymal Transition and Promotes Metastasis of Hepatocellular Carcinoma by Transcriptionally Activating &lt;i&gt;SNAIL&lt;/i&gt;

Supplementary Figure 2 from HNRNPAB Induces Epithelial–Mesenchymal Transition and Promotes Metastasis of Hepatocellular Carcinoma by Transcriptionally Activating <i>SNAIL</i>